阿尔尼拉姆制药公司
ALNY400.590USD
-0.100-0.02%
收盘 12/26, 16:00（美东）报价延迟15分钟
52.79B总市值
1233.61市盈率 TTM
关于 阿尔尼拉姆制药公司 公司
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
阿尔尼拉姆制药公司简介
公司代码ALNY
公司名称Alnylam Pharmaceuticals Inc
上市日期May 28, 2004
CEOGreenstreet (Yvonne L)
员工数量2230
证券类型Ordinary Share
年结日May 28
公司地址675 W Kendall St
城市CAMBRIDGE
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编02142-1168
电话16175518200
网址https://www.alnylam.com/
公司代码ALNY
上市日期May 28, 2004
CEOGreenstreet (Yvonne L)
阿尔尼拉姆制药公司公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
69.39K
+5.43%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
54.11K
+7.83%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
27.44K
+5.56%
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
4.41K
--
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
911.00
+569.85%
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Director
Independent Director
775.00
--
Mr. Peter N. Kellogg
Mr. Peter N. Kellogg
Independent Director
Independent Director
775.00
--
Ms. Colleen F. Reitan
Ms. Colleen F. Reitan
Independent Director
Independent Director
--
--
Ms. Amy W. Schulman, J.D.
Ms. Amy W. Schulman, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Pushkal P. Garg, M.D.
Dr. Pushkal P. Garg, M.D.
Executive Vice President, Chief Research and Development Officer
Executive Vice President, Chief Research and Development Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
69.39K
+5.43%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
54.11K
+7.83%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
27.44K
+5.56%
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
4.41K
--
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
911.00
+569.85%
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Director
Independent Director
775.00
--
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
业务USD
名称
营收
占比
AMVUTTRA
491.95M
63.59%
GIVLAARI
80.85M
10.45%
ONPATTRO
52.54M
6.79%
Other
50.67M
6.55%
OXLUMO
46.87M
6.06%
其他
50.81M
6.57%
地区USD
名称
营收
占比
United States
454.57M
58.75%
Europe
157.01M
20.29%
Net revenues from collaborations
61.50M
7.95%
Rest of World
60.63M
7.84%
Royalty revenue
39.98M
5.17%
业务
地区
业务USD
名称
营收
占比
AMVUTTRA
491.95M
63.59%
GIVLAARI
80.85M
10.45%
ONPATTRO
52.54M
6.79%
Other
50.67M
6.55%
OXLUMO
46.87M
6.06%
其他
50.81M
6.57%
股东统计
更新时间: 11月17日 周一
更新时间: 11月17日 周一
持股股东
股东类型
持股股东
持股股东
占比
Capital World Investors
12.44%
Fidelity Management & Research Company LLC
12.04%
The Vanguard Group, Inc.
10.22%
Capital Research Global Investors
5.47%
BlackRock Institutional Trust Company, N.A.
4.98%
其他
54.85%
持股股东
持股股东
占比
Capital World Investors
12.44%
Fidelity Management & Research Company LLC
12.04%
The Vanguard Group, Inc.
10.22%
Capital Research Global Investors
5.47%
BlackRock Institutional Trust Company, N.A.
4.98%
其他
54.85%
股东类型
持股股东
占比
Investment Advisor
66.37%
Investment Advisor/Hedge Fund
23.04%
Hedge Fund
3.83%
Research Firm
2.50%
Sovereign Wealth Fund
1.70%
Pension Fund
1.29%
Bank and Trust
1.20%
Corporation
1.05%
Individual Investor
0.42%
机构持股
更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
1441
132.38M
102.07%
-8.88K
2025Q3
1468
132.43M
102.39%
+2.53M
2025Q2
1335
129.81M
101.55%
+2.82M
2025Q1
1292
127.17M
99.72%
-2.77M
2024Q4
1248
125.34M
101.87%
-989.05K
2024Q3
1210
126.51M
99.20%
+3.13M
2024Q2
1165
122.70M
94.98%
+5.27M
2024Q1
1152
117.38M
97.56%
-6.00M
2023Q4
1149
120.10M
100.10%
-712.55K
2023Q3
1103
121.13M
101.32%
-503.11K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Capital World Investors
16.81M
12.82%
+55.38K
+0.33%
Jun 30, 2025
Fidelity Management & Research Company LLC
15.05M
11.48%
+427.38K
+2.92%
Jun 30, 2025
The Vanguard Group, Inc.
13.24M
10.1%
+238.24K
+1.83%
Jun 30, 2025
Capital Research Global Investors
7.19M
5.49%
+36.93K
+0.52%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
6.53M
4.98%
-199.00K
-2.96%
Jun 30, 2025
JP Morgan Asset Management
1.79M
1.37%
-87.08K
-4.64%
Jun 30, 2025
State Street Investment Management (US)
3.17M
2.42%
-193.48K
-5.75%
Jun 30, 2025
Baillie Gifford & Co.
3.03M
2.31%
-625.72K
-17.11%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.40M
1.83%
+75.94K
+3.27%
Jun 30, 2025
Dodge & Cox
3.20M
2.44%
-154.67K
-4.61%
Jun 30, 2025
查看更多
持股ETF
更新时间: 12月2日 周二
更新时间: 12月2日 周二
机构名称
占比
Global X Genomics & Biotechnology ETF
6.48%
ProShares Ultra Nasdaq Biotechnology
5.81%
Invesco Nasdaq Biotechnology ETF
5.77%
Franklin Genomic Advancements ETF
5.35%
iShares Biotechnology ETF
5.07%
VanEck Biotech ETF
4.56%
American Century Focused Dynamic Growth ETF
3.76%
Goldman Sachs Future Health Care Equity ETF
3.42%
First Trust NYSE Arca Biotechnology Index Fund
3.33%
Invesco NASDAQ Next Gen 100 ETF
3.28%
查看更多
Global X Genomics & Biotechnology ETF
占比6.48%
ProShares Ultra Nasdaq Biotechnology
占比5.81%
Invesco Nasdaq Biotechnology ETF
占比5.77%
Franklin Genomic Advancements ETF
占比5.35%
iShares Biotechnology ETF
占比5.07%
VanEck Biotech ETF
占比4.56%
American Century Focused Dynamic Growth ETF
占比3.76%
Goldman Sachs Future Health Care Equity ETF
占比3.42%
First Trust NYSE Arca Biotechnology Index Fund
占比3.33%
Invesco NASDAQ Next Gen 100 ETF
占比3.28%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
阿尔尼拉姆制药公司的前五大股东是谁？
阿尔尼拉姆制药公司 的前五大股东如下：
Capital World Investors持有股份：16.81M，占总股份比例：12.82%。
Fidelity Management & Research Company LLC持有股份：15.05M，占总股份比例：11.48%。
The Vanguard Group, Inc.持有股份：13.24M，占总股份比例：10.10%。
Capital Research Global Investors持有股份：7.19M，占总股份比例：5.49%。
BlackRock Institutional Trust Company, N.A.持有股份：6.53M，占总股份比例：4.98%。
Capital World Investors持有股份：16.81M，占总股份比例：12.82%。
Fidelity Management & Research Company LLC持有股份：15.05M，占总股份比例：11.48%。
The Vanguard Group, Inc.持有股份：13.24M，占总股份比例：10.10%。
Capital Research Global Investors持有股份：7.19M，占总股份比例：5.49%。
BlackRock Institutional Trust Company, N.A.持有股份：6.53M，占总股份比例：4.98%。
阿尔尼拉姆制药公司的前三大股东类型是什么？
阿尔尼拉姆制药公司 的前三大股东类型分别是：
Capital World Investors
Fidelity Management & Research Company LLC
The Vanguard Group, Inc.
Capital World Investors
Fidelity Management & Research Company LLC
The Vanguard Group, Inc.
有多少机构持有阿尔尼拉姆制药公司(ALNY)的股份？
截至2025Q4，共有1441家机构持有阿尔尼拉姆制药公司的股份，合计持有的股份价值约为132.38M，占公司总股份的102.07%。与2025Q3相比，机构持股有所增加，增幅为-0.32%。
哪个业务部门对阿尔尼拉姆制药公司的收入贡献最大？
在FY2025Q2，AMVUTTRA业务部门对阿尔尼拉姆制药公司的收入贡献最大，创收491.95M，占总收入的63.59%。
